Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RGX-202 · 1 trial · 1 indication
Evaluate incidences of AEs and SAEs
Proportion of participants whose RGX-202 microdystrophin protein expression determined in their muscle biopsy is ≥ 10% relative to dystrophin level in non-DMD participants
| Arm | Type | Description |
|---|---|---|
| Part 1: Cohort 1 and 1b (enrollment complete): RGX-202 Dose 1 | EXPERIMENTAL | A single IV infusion of RGX-202 at a dose of 1×10\^14 GC/kg body weight |
| Part 1: Cohort 2, 2c;, and Part 2; and Part 3 (enrollment complete for all): RGX-202 Dose 2 | EXPERIMENTAL | A single IV infusion of RGX-202 at a dose of 2x10\^14 GC/kg body weight (or a fixed dose of 1.00×10\^16 GC \[150 mL\] for participants weighing \> 50 kg) |
| Name | Type | Description |
|---|---|---|
| RGX-202 | GENETIC | RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin |
Part 1 - Key Inclusion Criteria: * The participant's legal guardian(s) is (are) willing and able to provide written, signed informed consent prior to any study-related procedures; and, where applicable, the minor participant has provided written or verbal assent according to local requirements. * I...
RGX-202 is an investigational gene therapy being developed for Duchenne Muscular Dystrophy (DMD), a rare genetic muscle-wasting disease. It is designed as a one-time treatment for patients with DMD and is currently in Phase 2 clinical development. It has not been approved by the FDA.
RGX-202 targets dystrophin, the protein missing or defective in Duchenne Muscular Dystrophy. It is a gene therapy designed to deliver a functional version of the dystrophin gene to muscle cells, aiming to restore dystrophin production. Dystrophin is essential for muscle fiber stability and function.
RGX-202 is being developed by REGENXBIO Inc., a clinical-stage biotechnology company. REGENXBIO trades on the Nasdaq under the ticker symbol RGNX. The company is the sponsor of the ongoing clinical trial for RGX-202 in Duchenne Muscular Dystrophy.
RGX-202 is in Phase 2 clinical development. It is an investigational gene therapy and has not been approved by the FDA for any indication. The Phase 2 trial is currently active but not recruiting participants.
RGX-202 is being evaluated in a single Phase 2 clinical trial, NCT05693142, titled AFFINITY DUCHENNE. The trial is active but not recruiting and has an estimated enrollment of 65 male participants aged 1 year and older. It is conducted in the United States and Canada.
Yes, RGX-202 has received three FDA designations: Fast Track, Orphan Drug, and Rare Pediatric Disease. These designations are intended to support and expedite the development of therapies for serious rare diseases. RGX-202 remains investigational and has not been approved.